Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.

The Company also reported that all available patients from the ANA598 200 mg arm who were previously reported to have undetectable levels of virus at Week 24 and continued on pegylated interferon and ribavirin (current standard of care, or SOC) also maintained undetectable levels of virus at Week 36.  In addition, all patients from the ANA598 400 mg arm who were previously reported to have undetectable levels of virus at Week 12 and continued on SOC maintained undetectable levels of virus at Week 24.  ANA598, Anadys' direct-acting antiviral or DAA, is being developed to treat hepatitis C and is in an ongoing Phase II trial in combination with pegylated interferon and ribavirin.

"The SVR12 data reported today for ANA598 are highly encouraging," said Steve Worland, Ph.D., President and CEO of Anadys.  "These data illustrate the potential for HCV patients to be successfully treated with shortened courses of treatment, reflecting the continuing benefit of ANA598 post-therapy.  We believe these data, coupled with the excellent barrier to resistance demonstrated in this trial as well as the favorable safety and tolerability, confirm ANA598's position as one of the most attractive agents in Phase II HCV development today."

The si
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... that provides the Company with flexibility and control to ... has signed an equity purchase agreement for up to ... a Chicago -based institutional investor, which ...
(Date:7/29/2015)... 2015  Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2015 on Wednesday, August 5, 2015, after the close of ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ... through a link that is posted on the home page ...
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider ... recently announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency ... providers. 24/7 Care At Home’s agency is one of three top Orange County agencies ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater ... comfort to patients as well as visiting friends and family during these critical moments, ... , The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently ...
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... continues to expand, as the company and UCLA’s Jonsson Comprehensive Cancer Center ... OncLive announced today. With the new collaboration, OncLive’s editorial and marketing groups will ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Zaichik Creates New Tool That Increases Training Capability , World renown ... tool called Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... announced today that the latest issue of Inclusive™ magazine, its multimedia publication focused ... The digital edition of the new issue, Volume 6, Issue 2, as well ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... children and adolescents in the United States had physician-diagnosed ... major national study called SEARCH for Diabetes in Youth. ... among youth under the age of 20 ever conducted ... M.S., associate professor of epidemiology and prevention at Wake ...
... antibiotic shows early promise as an anti-cancer agent, inhibiting ... tumors, // according to researchers at the University of ... appear in the Oct. 1 issue of Cancer Research. ... to be over-expressed in cancer cells to screen for ...
... to rebuild after years of dictatorship and war, Iraqi ... // in treating many of the most serious injuries ... important step forward was last year's "Kuwait Plast 2005" ... and American counterparts in a 5-day exchange of surgical ...
... of Standards and Technology (NIST) are developing a robotic ... powered mobility and the ability, depending on patient status, ... without assistance. ,The lifting ability of the system, ... Position and Rehabilitation), also should significantly reduce caregiver and ...
... (TPVs) are more likely to suffer severe, persistent ... permanent protection visas (PPVs) // , specialist trauma ... post-traumatic stress disorder (PTSD) and depression are much ... holders, mental health professionals from the Sydney-based Service ...
... severe gastroenteritis should now be made available to all ... of the Medical Journal of Australia. // ... effective tool to prevent a common, miserable disease affecting ... say in an editorial. ,“Rotavirus vaccine is ...
Cached Medicine News:Health News:One in 523 Children and Adolescents Have Diabetes 2Health News:One in 523 Children and Adolescents Have Diabetes 3Health News:Antibiotic Inhibits Cancer Gene Activity 2Health News:Journal of Craniofacial Surgery Publishes Research by Iraqi Surgeons 2Health News:Robot Wheelchair Maybe Helpful for Wheelchair-dependent Patients 2Health News:Detention, Uncertainty take their Toll on the Mental Health of Refugees 2Health News:Experts Call for Rotavirus Vaccine for All 2
MBP's extra long 200 L pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
... is an immunometric ('sandwich') EIA for ... human serum or plasma. LH in ... monoclonal anti-LH antibodies directed at different ... magnetic particles and the other is ...
... is an HPLC system designed to provide ... levels and aid in the comprehensive identification ... results for glycemic control., ,The A1c assay ... with the accuracy of boronate affinity columns. ...
... of the fastest blood gas ... care situations on the market. ... lung function testing. The ... quick and reliable assessment of ...
Medicine Products: